Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

Running, not enrolling · Phase 1/Phase 2

Conditions studied: HNSCC

In brief

To Study Perioperative PD-1 Inhibitor and Cesium-131 Interstitial Brachytherapy in patients with locally recurrent HNSCC eligible for salvage surgery.

Key facts

Study ID

NCT04340258

Run by

University of Cincinnati

People needed

50

Starts

2021-02-04

Expected to finish

2026-09-04

Last updated by the study team

2026-06-09

Who can join

Age: 19 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• locally recurrent HNSCC and be eligible for salvage surgery
• If patient received radiation therapy in the past, they should have recovered from the acute toxicity to <grade 1
• tumor needs to be deemed resectable

You may not qualify if…

• Exposed carotid artery preoperatively requiring sacrifice or bypass intra-operatively
• Patients with active pharyngo-cutaneous
• Patients with more than one site of distant metastatic disease
• Prior immune-based anticancer therapy within last six months

Where it is running

• University of Cincinnati Medical Center — Cincinnati, Ohio, United States
• Thomas Jefferson — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.